Cannabis-based medicines in multiple sclerosis--a review of clinical studies.
For some years a mixture of anecdotal report and data from animal models have implied a potential role for cannabis-based medicines in ameliorating a variety of symptoms of multiple sclerosis. Only recently however have large randomised controlled trials (RCTs) examined these potential effects rigorously. At present the results of RCTs have lacked a coherent message to the prescribing clinician and reasons for such heterogeneity in cannabinoid trials are discussed.
Rog
David J
DJ
Greater Manchester Neurosciences Centre, Stott Lane, Manchester M68HD, UK. David.Rog@srft.nhs.uk
D002186:Cannabinoids / Q000627:therapeutic use*; D002188:Cannabis; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D008517:Phytotherapy; D016032:Randomized Controlled Trials as Topic
D002186:Cannabinoids